TNF-α LYTAC (Biohaven)

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameTNF-α LYTAC (Biohaven)
Drug Alias NameN/A
ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)
Mechanisms of ActionTumor necrosis factor α degradersAsialoglycoprotein receptor binders
TargetsTumor necrosis factor αAsialoglycoprotein receptor
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiohaven Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiohaven Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A